Compounds > triazoles
Page last updated: 2024-08-24

triazoles and sorafenib

triazoles has been researched along with sorafenib in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (57.14)24.3611
2020's6 (42.86)2.80

Authors

AuthorsStudies
Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG1
Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M1
Gradishar, WJ1
Baker, SD; Chaudhry, AS; Finkelstein, D; Gibson, A; Inaba, H; Li, L; Roberts, JL; Rubnitz, JE; Schuetz, EG; Zimmerman, EI1
Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V1
Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L1
Gong, P; Qin, M; Yao, Q; Ye, W; Yu, S1
Geng, P; Liu, Y; Qin, J; Sun, M; Sun, X; Wu, C; Wu, Y; Yin, Y; Zhan, X; Zhang, S; Zhuang, Z1
Abdouni, A; Allende, DS; Apte, SS; Arechederra, M; Audebert, S; Bazai, SK; Daian, F; Dono, R; Gregoire, D; Hibner, U; Lozano, A; Maina, F; Mead, TJ; Richelme, S; Sequera, C1
Boonsombat, J; Chuaypen, N; Ketkaew, Y; Limpachayaporn, P; Palakhachane, S; Ruchirawat, S; Sirirak, J; Suksamrarn, A; Tangkijvanich, P1
Al-Hossaini, AM; Al-Mehizi, AA; Alanazi, MM; Alkahtani, HM; Alsaif, NA; Elwan, A; Mahdy, HA; Obaidullah, AJ; Taghour, MS1
Arafa, RK; Balkan, A; Unsal Tan, O; Zengin, M1
Abulkhair, HS; Fayed, EA; Husseiny, EM; Othman, EM1
Charoensuksai, P; Chuaypen, N; Limpachayaporn, P; Nuchpun, S; Sirirak, J; Suksamrarn, A; Tangkijvanich, P; Wongprayoon, P1

Reviews

1 review(s) available for triazoles and sorafenib

ArticleYear
Sorafenib in locally advanced or metastatic breast cancer.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles

2012

Trials

2 trial(s) available for triazoles and sorafenib

ArticleYear
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
    Breast cancer research and treatment, 2011, Volume: 125, Issue:1

    Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Sorafenib; Stem Cells; Time Factors; Treatment Outcome; Triazoles; United States

2011
Ontogeny and sorafenib metabolism.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Oct-15, Volume: 18, Issue:20

    Topics: Adolescent; Age Factors; Azoles; Child; Child, Preschool; Cytochrome P-450 CYP3A; Female; Humans; Infant; Infant, Newborn; Liver; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sex Factors; Sorafenib; Triazoles; Voriconazole; Young Adult

2012

Other Studies

11 other study(ies) available for triazoles and sorafenib

ArticleYear
Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Breast cancer research and treatment, 2010, Volume: 124, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Aromatase; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Caspase 7; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Niacinamide; Nitriles; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Testosterone; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazoles

2010
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
    British journal of cancer, 2015, Jan-06, Volume: 112, Issue:1

    Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Triazoles

2015
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
    The Journal of pharmacology and experimental therapeutics, 2017, Volume: 362, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays

2017
Synthesis and Antitumor Activity of Triazole-Containing Sorafenib Analogs.
    Molecules (Basel, Switzerland), 2017, Oct-24, Volume: 22, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Catalysis; Cell Proliferation; Cell Survival; Coordination Complexes; Copper; Cycloaddition Reaction; HT29 Cells; Humans; Sorafenib; Structure-Activity Relationship; Triazoles

2017
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Journal of experimental & clinical cancer research : CR, 2019, Feb-15, Volume: 38, Issue:1

    Topics: Animals; Antineoplastic Agents; Azepines; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Mice; Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Triazoles; Xenograft Model Antitumor Assays

2019
ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    Journal of hepatology, 2021, Volume: 74, Issue:4

    Topics: ADAMTS Proteins; ADAMTS5 Protein; Animals; Antineoplastic Agents, Immunological; Benzocycloheptenes; Carcinogenesis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epigenomics; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Phenylurea Compounds; Quinolines; Signal Transduction; Sorafenib; Transcriptional Activation; Triazoles; Tumor Microenvironment

2021
Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines.
    Bioorganic chemistry, 2021, Volume: 112

    Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Sorafenib; Structure-Activity Relationship; Triazoles; Wound Healing

2021
Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
    Archiv der Pharmazie, 2022, Volume: 355, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Female; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Mice; Quinoxalines; Rats; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2

2022
Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.
    Bioorganic chemistry, 2022, Volume: 121

    Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2

2022
The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia.
    Bioorganic chemistry, 2022, Volume: 127

    Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Molecular Docking Simulation; Molecular Structure; Semicarbazones; Sorafenib; Structure-Activity Relationship; Thiosemicarbazones; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2022
meta-Ureidophenoxy-1,2,3-triazole hybrid as a novel scaffold for promising HepG2 hepatocellular carcinoma inhibitors: Synthesis, biological evaluation and molecular docking studies.
    Bioorganic & medicinal chemistry, 2022, Nov-15, Volume: 74

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2

2022